Vincerx Pharma, Inc.
VINCU
NASDAQ Global Select27.00
USD
- -
- -
CIK
0001796129
CUSIP
92731L205
Return %
Stock
S&P500
1Y
- -
19.01
3Y
163.41
65.48
5Y
163.41
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 42
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 260 Sheridan Avenue Palo Alto CA United States of America 94306
- IPO Date
- Dec 29, 2020
- CIK
- 0001796129
- Website
- vincerx.com
- Similar Companies
- Business
- Vincerx Pharma, Inc. (Nasdaq: VINC; OTC: VINCU) is a clinical-stage biopharmaceutical company that develops differentiated oncology therapies addressing unmet needs in cancer patients through its proprietary VersAptx bioconjugation platform and related technologies; core assets include VIP943, a next-generation CD123-targeted antibody-drug conjugate (ADC) in Phase 1 for leukemias and myelodysplastic syndromes (MDS), VIP236, a small molecule drug conjugate (SMDC) in Phase 1 for advanced solid tumors, VIP924, a preclinical CXCR5-targeted ADC for B-cell malignancies, and enitociclib (VIP152), a selective PTEFb (CDK9) inhibitor that has completed Phase 1 monotherapy studies in solid tumors, non-Hodgkin lymphoma and acute myeloid leukemia with early efficacy signals in double-hit diffuse large B-cell lymphoma. Founded in 2019 and headquartered in Palo Alto, California, with a research subsidiary in Monheim, Germany, the company targets hematologic malignancies and solid tumors such as breast, lung, ovarian and prostate cancers primarily in the United States and Europe. In December 2024, Vincerx entered a binding term sheet for a strategic merger with Oqory, Inc., adding Oqory's Phase 3 anti-TROP2 ADC OQY-3258 (ESG401) for triple-negative and HR+/HER2- breast cancer to the pipeline, with Oqory shareholders expected to own 95% of the combined entity pending definitive agreement, $20 million equity financing, regulatory approvals and Nasdaq listing; subsequent leadership changes positioned Raquel Izumi, Ph.D. as Acting CEO while pursuing cost controls including workforce reductions.